Oral arguments by Illumina and Grail before the US Federal Trade Commission today focused on the competitive impact of the merger on lives saved through Grail’s cancer-detecting blood test, and on the parties’ proposed “open offer” to customers of its gene-sequencing platform.The five commissioners heard arguments in the appeal
* = Required Field
*Areas of Interest
MLex content is primarily organized into seven Areas of Interest that cover the main elements of regulatory risk.
Please indicate which ones you would like to be included in your Daily Wrap-up alert
Serafina Smith covers mergers and acquisitions for MLex from New York. Before becoming a journalist, Serafina was a paralegal supporting the United States Department of Justice, where she worked on foreign bribery and money laundering cases. She holds a master’s degree in journalism from New York University and a bachelor’s degree in linguistics from Georgetown University.